Big effect
Vitamin D lowered a key inflammation marker by 39% in a 12-week trial — but only in colorectal cancer patients with low starting levels.
This striking drop in interleukin-6 is promising for reducing inflammation in a clinical setting, though the broader evidence for vitamin D's anti-inflammatory effects is mixed, and the same study found no benefit for two other inflammatory markers.
In a double-blind trial, colorectal cancer patients with low vitamin D status received a personalized loading dose followed by 2,000 IU daily for 12 weeks. Their blood levels of interleukin-6 — a protein involved in chronic inflammation — fell by 39% relative to placebo. However, two other inflammation-related markers did not budge, and the results may not apply to healthy people or those with sufficient vitamin D.
Where this fits in the evidence
Pillser has synthesized 8 studies on Vitamin D for Reduced Interleukin-6 Levels — overall evidence strength: Moderate.
Vitamin D supplementation shows moderate evidence for reducing IL-6 levels. Among 8 studies, 5 reported beneficial effects with a predominant moderate effect size, while 3 found no significant change. The median study duration was 56 days, and most studies used daily doses between 200 and 5000 IU in clinical populations such as colorectal cancer patients, overweight/obese adults, and those with low-grade inflammation.
The study
- Randomized Controlled Trial (RCT)
- n = 126
- 2026-01-08
- British journal of cancer
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.